Background: Myostatin, also known as Growth and Differentiation Factor 8, is a secreted protein that inhibits muscle growth. Disruption of myostatin signaling increases muscle mass and decreases glucose, but it is unclear whether these changes are related. We treated mice on chow and high-fat diets with a soluble activin receptor type IIB (ActRIIB, RAP-031), which is a putative endogenous signaling receptor for myostatin and other ligands of the TGF-b superfamily. Results: After 4 weeks, RAP-031 increased lean and muscle mass, grip strength and contractile force. RAP-031 enhanced the ability of insulin to suppress glucose production under clamp conditions in high-fat fed mice, but did not significantly change insulin-mediated glucose disposal. The hepatic insulin-sensitizing effect of RAP-031 treatment was associated with increased adiponectin levels. RAP-031 treatment for 10 weeks further increased muscle mass and drastically reduced fat content in mice on either chow or high-fat diet. RAP-031 suppressed hepatic glucose production and increased peripheral glucose uptake in chow-fed mice. In contrast, RAP-031 suppressed glucose production with no apparent change in glucose disposal in high-fat-diet mice. Conclusion: Our findings show that disruption of ActRIIB signaling is a viable pharmacological approach for treating obesity and diabetes.
Introduction
Myostatin is a member of the TGF-b superfamily that is predominantly expressed and secreted by the skeletal muscle. 1 Loss-of-function mutations in the myostatin gene result in a massive increase in muscle mass in mice, cattle, dogs and humans. [1] [2] [3] [4] The biology of myostatin has been explored pharmacologically through the injection of neutralizing antibodies or the myostatin propeptide, both of which increase muscle mass in mice. [5] [6] [7] Proteins that bind to myostatin, for example, follistatin, follistatin-related gene, and growth and differentiation factor-associated serum protein-1, result in the inhibition of myostatin activity and increased muscle growth. 8 In addition to its effects on muscle, myostatin has been reported to promote or inhibit adipogenesis. [9] [10] [11] The activin type IIB receptor (ActRIIB) is a signaling receptor for multiple TGF-b superfamily members, including activin A, nodal, BMP2, BMP6, BMP7, GDF5, GDF8 (myostatin) and GDF11, which are involved in the negative regulation of muscle. ActRIIB is widely distributed in the skeletal muscle, adipose tissue and various organs. 12 Myostatin and ActRIIB levels are altered in obese mice. 13 Interestingly, myotubes from extremely obese individuals secrete high levels of myostatin, and this is related to the severity of insulin resistance. 14 Obesity is characterized by increased fat content and relative decrease in lean tissue; thus, it was postulated that inhibition of myostatin would increase lean and muscle mass and ameliorate insulin resistance and diabetes. 15, 16 In agreement, crossing myostatin knock-out mice with Lep ob/ob and agouti lethal yellow (A y /a) mice attenuated body fat and glucose levels. 17 Myostatin-deficient mice generated from ENU mutagenesis manifested reduced fat content and improved hepatic insulin sensitivity on high-fat diet. 16 Disruption of myostatin signaling through transgenic myostatin propeptide expression also prevented diet-induced obesity and insulin resistance. 18 However, these genetic models do not clarify whether the effect of myostatin deficiency on glucose homeostasis is directly attributable to increased muscle mass. A soluble ActRIIB/Fc fusion protein (RAP-031) has been shown to increase muscle mass and strength in a mouse model of amyotrophic lateral sclerosis. 19 In this study, we treated mice on chow or high-fat diets with this compound, and studied the temporal relationships between body composition and insulin sensitivity. ; provided by Acceleron Pharmaceuticals, Cambridge, MA, USA) was injected intraperitoneally twice weekly. 19 Preliminary studies showed that RAP-031 treatment increased lean and muscle mass in a dose-dependent manner. vehicle. Food intake was measured weekly, and body composition was assessed before treatment, and 4 and 10 weeks later with nuclear magnetic resonance (NMR) (Echo Medical Systems, Houston, TX, USA).
Materials and methods

Animals and treatment
21,22
Treadmill and muscle studies RAP-031-or vehicle-treated mice were acclimatized to a modular treadmill connected to an open circuit indirect calorimeter (CLAMS, Columbus Instruments, Columbus, OH, USA). After 4 weeks of treatment, the mice were deprived of food for 5 h, and indirect calorimetry was performed at rest for 1 h followed by forced exercise on the treadmill (angle 101 15 min at 10 m min À1 and then 2 h at 15 m min
À1
). The muscle strength in the forelimbs was measured with a grip meter (TSE; Bad, Hamburg, Germany). The mice were trained to grasp a horizontal metal bar while being pulled by their tail, and the force was detected by a sensor. Ten measurements were determined for each mouse and averaged. The mice were euthanized with carbon dioxide, muscles were dissected and weighed, and contraction of the extensor digitorum longus (EDL) muscle was analyzed ex vivo. Twitch and tetanic responses were evaluated as previously described. 5, 23, 24 At the end of the physiological studies, muscles were flash-frozen in isopentane cooled in liquid nitrogen and stored at À80 1C before sectioning. Serial frozen sections (10 mm) were cut at the mid belly of the EDL muscle, fixed using 100% ice-cold methanol (5 min), and stored in airtight containers at À80 1C. Sections were examined after staining with hematoxylin and eosin or ATPase. Pictures were taken using an Olympus BX51 microscope equipped with a Magnafire camera. Morphometric measurements were performed on digitized images using the Scion Image 4.02 software (Frederick, MD, USA) as previously described. Hyperinsulinemic-Euglycemic clamp RAP-031 or vehicle-treated mice on normal chow or high-fat diets for 4 or 10 weeks, respectively underwent hyperinsulinemic-euglycemic clamp to assess glucose kinetics. 21, 22 An indwelling catheter was inserted in the right internal jugular vein under sodium pentobarbital anesthesia and extended to the right atrium. Four days after recovery, the mice were fasted for 6 h (0800-1300), placed in restrainers and administered a bolus injection of 5 mCi of H] glucose, followed by continuous intravenous infusion at 0.05 mCi min
. Baseline glucose kinetics were measured for 60 min, followed by hyperinsulinemic clamp for 120 min. A priming dose of regular insulin (16 mU kg À1 , Humulin; Eli Lilly, Indianapolis, IN, USA) was given intravenously, followed by continuous infusion at 2.5 mU kg À1 min
. A variable intravenous infusion of 20% glucose was administered to attain blood glucose levels of 120-140 mg per 100 ml. The target glucose concentration was maintained for 90 min. The mice were euthanized, and liver, perigonadal white adipose tissue (WAT), and soleus/gastrocnemius muscles were excised, frozen immediately in liquid nitrogen and stored at À80 1C for analysis of glucose uptake. Rates of whole body glucose uptake and basal glucose turnover are measured as the ratio of the [ 3 H] glucose infusion rate (d.p.m.) to the specific activity of plasma glucose. Hepatic glucose production (HGP) during clamp is measured by subtracting the glucose infusion rate (GIR) from the whole body glucose uptake (Rd).
Chemistry RAP-031 or vehicle-treated mice on normal chow or high-fat diets for 4 or 10 weeks, respectively, were deprived of food from 0800 to 1300 h, and then euthanized with carbon dioxide. Cardiac blood was drawn and serum was stored at À20 1C Serum glucose and lipids were measured using colorimetric enzymatic assays (Stanbio, Boerne, TX, USA). Insulin, leptin and adiponectin were measured with enzyme immunoassays (Crystal Chem, Evanston, IL, USA; Linco, St Charles, MO, USA). 400  600  800  1000  1200  1400  1600  1800  2000  2200  2400  2600  2800  3000  3200  3400   0  200  400  600  800  1000  1200  1400  1600  1800  2000  2200  2400  2600  2800  3000  3200  3400  3600 ActRIIB regulates muscle mass and insulin sensitivity I Akpan et al
Statistical analysis
The effect of RAP-031 treatment on various parameters within each diet group was assessed using unpaired t-test. Po0.05 is significant. (Figures 2a-d) .
Results
Short
RAP-031 treatment did not significantly alter the basal or peak VO 2 levels during treadmill exercise (Figures 3a, b) , or the respiratory quotient (RQ) under basal or peak exercise conditions (data not shown). On the other hand, the forelimb grip strength was increased by RAP-031 on both chow and high-fat diets (Figure 3c ). EDL twitch force was increased by RAP-031 treatment (Figure 3d) . Moreover, EDL contraction under tetanic stimulation was enhanced by RAP-031 in high-fat fed mice (Figure 3e) .
RAP-031 treatment for 4 weeks resulted in an elevation of serum adiponectin in high-fat fed mice, but glucose, lipids, insulin and leptin were not significantly different (Table 1 ). We performed hyperinsulinemic-euglycemic clamp with radioisotopic tracers to examine the effects of 4 weeks ActRIIB regulates muscle mass and insulin sensitivity I Akpan et al RAP-031 treatment on glucose homeostasis. The basal glucose production was not significantly affected by RAP-031 treatment in chow-fed mice (Figure 4a ). Moreover, we did not detect a statistically significant difference in the glucose infusion rate (GIR) needed to maintain euglycemia in vehicle and RAP-031-treated mice under insulin clamp (Figure 4a ). HGP, glucose disposal rate (Rd) and glucose uptake by WAT and muscle under insulin clamp were not different between chow-fed mice treated with RAP-031 or vehicle (Figures 4a, b) . In contrast, RAP-031 treatment increased GIR (43.9 ± 4.33 vs 27 ± 6 ml kg À1 min
À1
, P ¼ 0.03) in mice on a high-fat diet, consistent with improvement of insulin sensitivity (Figure 4c ). The ability of insulin to suppress HGP (25.3±2.9 vs 33.7±2.1 ml kg À1 min À1 , P ¼ 0.047) was enhanced by RAP-031, but we did not detect a statistically significant effect of RAP-031 on Rd (69.2±2.35 vs 60.7±4.48 ml kg À1 min
, P ¼ 0.12) (Figure 4c ), or glucose uptake by WAT or muscle (Figure 4d ).
Long-term RAP-031 treatment increases muscle mass, decreases fat and enhances insulin sensitivity RAP-031 treatment did not significantly alter body weight at 10 weeks (Figure 5a ), but increased lean mass (Figure 5b ).
Body fat was drastically reduced by RAP-031 after 10 weeks (Figures 5c-i) . Serum levels of leptin, glucose and cholesterol levels fell in parallel with reduced adiposity in high-fat diet mice after RAP-031 treatment (Table 2 ). Adiponectin concentration in the serum was highly variable and did not change significantly after 10 weeks RAP031 treatment (Table 2) . However, on the high-fat diet, the ratio of serum adiponectin-to-body fat was higher in mice treated with RAP-031 than vehicle (1.42 vs 0.76). The basal glucose production rate was not significantly different between vehicle or RAP-031-treated mice on chow diet (Figure 6a) , P ¼ 0.008) (Figure 6a ). Insulinstimulated glucose uptake in WAT and muscle was increased by RAP-031 (Figure 6b ). On the high-fat diet, RAP-031 increased GIR (43.3 ± 3.9 vs 27.8 ± 2.7 ml kg À1 min
, P ¼ 0.03) and suppressed HGP (6.78±0.5 vs 22.3±4.8 ml kg À1 min
, P ¼ 0.008) (Figure 6c ), but did not change Rd (50.2 ± 3.5 vs 51.1 ± 3.3 ml kg À1 min
, P ¼ 0.12) or glucose uptake by WAT or muscle (Figure 6d ).
Discussion
There is evidence to suggest that multiple ligands including myostatin control muscle growth by signaling through ActRIIB. 15 We confirm here with the use of RAP-031 that disrupting ActRIIB signaling leads to increased muscle mass and improved functional parameters such as grip strength and ex vivo muscle contraction. 19 This increase in functional muscle mass occurs rapidly within 4 weeks of treatment, and is in agreement with published reports on myostatin knockout (Mstn-/-)mice, 2, 16 transgenic myostatin propeptide overexpression, 18 chronic administration of anti-myostatin antibodies 5, 19 and myostatin propeptide antibodies 6, 7 and viral overexpression of myostatin inhibitors. 8 The change in EDL mass and contraction force after 4 weeks of RAP-031 treatment is similar to that of 10 to 12-month-old Mstn heterozygous and null mice. 25 However, unlike MstnÀ/À mice, our results showed that RAP-031 treatment resulted in muscle hypertrophy rather than hyperplasia. 23 Obesity is associated with increased accumulation of fat and a relative decrease in lean and muscle mass. 26 Adipose tissue has been linked to insulin resistance and type 2 diabetes through the secretion of fatty acids, adipokines and proinflammatory cytokines. 27 Skeletal muscle is normally responsible for more than 75% of insulin-mediated glucose disposal, thus the reduction in muscle mass associated with obesity is thought to contribute to the development of insulin resistance and type 2 diabetes. 27, 28 Other factors implicated in skeletal muscle insulin resistance include the accumulation of intramyocellular lipids and metabolites, ActRIIB regulates muscle mass and insulin sensitivity I Akpan et al such as diacylglycerol and ceramides. 29, 30 Low-grade chronic inflammation and oxidative stress also contribute to skeletal muscle insulin resistance. 28 In contrast to the secretion of proinflammatory cytokines by adipose tissue, studies indicate that IL-6 is secreted by skeletal muscle during exercise and stimulates the release of other anti-inflammatory cytokines, for example, IL-1ra and IL-10, which inhibit the production of TNFa. In addition, IL-6 stimulates lipolysis and fat oxidation, thereby preventing fat accumulation in muscle and liver. 31 Thus, it appears IL-6 is a muscle-secreted peptide (myokine) that protects against diabetes and cardiovascular disease. 31 In contrast, myostatin secretion is increased in extremely obese women and associated with insulin resistance. 14 Myostatin treatment in mice induces insulin resistance. 16 Several lines of evidence led us to believe that postnatal inhibition of ActRIIB signaling would increase muscle, reduce fat and lead to improved glucose homeostasis. Myostatin and ActRIIB expression is altered in adipose tissue and skeletal muscle of obese mice. 13 MstnÀ/Àmice have increased muscle, decreased fat and improved insulin sensitivity. 16, 17 Similarly, transgenic mice overexpressing the myostatin propeptide that blocks myostatin signaling develop improved glucose tolerance and insulin sensitivity on a high-fat diet. 18 However, in vivo myostatin treatment has produced inconsistent effects on muscle and fat. Zimmers et al. 32 reported that subcutaneous injection of 2 mg myostatin for 7 days decreased body fat in female mice. These results could not be reproduced in another study. 33 Instead, 120 mg myostatin administered for 21 days decreased muscle mass without changing fat in wild type or genetically obese mice. 33 Our study revealed an interesting dynamic between body composition and glucose homeostasis following RAP-031 treatment. As predicted, RAP-031 rapidly increased lean and muscle mass. However, this did not lead to a significant enhancement of insulin-mediated glucose disposal in muscle or fat of mice on chow or high-fat diet. Instead, 4 weeks of RAP-031 treatment in high-fat diet mice resulted in a significant increase in insulin's effect to suppress glucose production. Interestingly, the hepatic insulin-sensitizing action of RAP-031 was associated with the elevation of adiponectin levels. Adiponectin is expressed in adipose tissue, circulates as low and high molecular weight complexes, and has been shown to enhance insulin sensitivity. 34 Similar to our results, transgenic overexpression of myostatin propeptide in mice fed a high-fat diet resulted in elevation of adiponectin levels. 7 The expression of adiponectin mRNA in epidydimal fat of transgenic myostatin propeptide mice was 12 times higher than in wild-type littermates, suggesting that enhanced muscle growth somehow stimulates the expression of adiponectin. 7 We observed that longer RAP-031 treatment for 10 weeks increased muscle mass, decreased body fat content that significantly increased hepatic and peripheral insulin sensitivity, particularly in chow-fed mice. Adiponectin concentration in the serum was not significantly increased by RAP-031, however, the ratio of adiponectin to body fat was greater, suggesting an increase in adiponectin secretion. The insulin-sensitizing action of adiponectin has been associated with fatty acid oxidation, which may be a potential mechanism for RAP-031. 34 The ability of prolonged RAP-031 treatment to improve sensitivity in the liver and peripheral organs is related to muscle hypertrophy and loss of body fat, respectively. A similar phenotype resulted from chronic activation of Akt signaling in skeletal muscle. 35 As with RAP-031 treatment, constitutive Akt expression in skeletal muscle caused skeletal muscle hypertrophy, increased strength, diminished fat deposition and improvement in whole body metabolism. 35 Interestingly, the anti-obesity effect of Akt activation was attributed to increased fatty acid oxidation in muscle. 35 Based on these findings, it was proposed that muscle-secreted proteins (known as myokines), serve as critical signals linking muscle to liver, adipose tissue and various organs. Indeed, follistatinlike 1 has recently been identified as a myokine that promotes limb vascularization. ActRIIB regulates muscle mass and insulin sensitivity I Akpan et al
